ArticleOncotarget2015
Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma.Oncoimmunology · 2025Article
- Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.Cancer medicine · 2024Review
- Construction of Orthogonal Modular Proteinaceous Nanovaccine Delivery Vectors Based on mSA-Biotin Binding.Nanomaterials (Basel, Switzerland) · 2022Article
- Immune cell labelling and tracking: implications for adoptive cell transfer therapies.EJNMMI radiopharmacy and chemistry · 2021Review
- CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
- Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.Oncoimmunology · 2020Article
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nature reviews. Clinical oncology · 2020Review
- T Cell Reprogramming Against Cancer.Methods in molecular biology (Clifton, N.J.) · 2020Review
- An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.Scientific reports · 2019Article
- Functional expression of monomeric streptavidin and fusion proteins in Escherichia coli: applications in flow cytometry and ELISA.Applied microbiology and biotechnology · 2018Article
- The development of CAR design for tumor CAR-T cell therapy.Oncotarget · 2018Review
- Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.Experimental and therapeutic medicine · 2017Article
- New development in CAR-T cell therapy.Journal of hematology & oncology · 2017Review
- The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Journal of Cancer · 2017Review
- Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.Theranostics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been significant progress in the design of chimeric antigen receptors (CAR) for adoptive immunotherapy targeting tumor-associated antigens. However, the challenge of monitoring the therapy in real time has been continually ignored. To address this issue, we developed optical molecular imaging approaches to evaluate a recently reported novel CAR strategy for adoptive immunotherapy against glioma xenografts expressing EGFRvIII. We initially biotinylated a novel anti-EGFRvIII monoclonal antibody (biotin-4G1) to pre-target EGFRvIII+ gliomas and then redirect activated avidin-CAR expressing T cells against the pre-targeted biotin-4G1. By optical imaging study and bio-distribution analysis, we confirmed the specificity of pre-target and target and determined the optimal time for T cells adoptive transfer in vivo. The results showed this therapeutic strategy offered efficient therapy effect to EGFRvIII+ glioma-bearing mice and implied that optical imaging is a highly useful tool in aiding in the instruction of clinical CAR-T cells adoptive transfer in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.